Skip to main content
  • Alembic Pharma receives USFDA Approval for Diclofenac Sodium Topical Solution Pradip Mahajan Thu, 12/01/2022 - 15:36

    Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world.

  • Gland Pharma acquires Europe based Cenexi Group Pradip Mahajan Wed, 11/30/2022 - 15:55

    The Singapore based subsidiary of Gland Pharma has acquired Europe based Cenexi Group which is engaged primarily in the business of Contract Development & Manufacturing Organisation (CDMO) of pharmaceutical products with expertise in sterile liquid and lyophilized fill- finished drugs, including capabilities on oncology and complex products.

    The Gland Pharma entered into a put option agreement to acquire 100 percent of Cenexi Group for an Equity Value not exceeding Euro 120 Mn (Enterprise Value of Euro 230 Mn).

  • Boston Scientific Announces agreement to acquire Apollo Endosurgery, Inc. Pradip Mahajan Wed, 11/30/2022 - 15:50

    Boston Scientific Corporation announced it has entered into a definitive agreement to acquire Apollo Endosurgery, Inc for a cash price of 10 USD per share, reflecting an enterprise value of approximately 615 million USD.

  • AstraZeneca to sale its US based plant Pradip Mahajan Wed, 11/30/2022 - 15:41

    AstraZeneca announces the sale of its West Chester site in Ohio, US, to National Resilience, Inc. (Resilience), a technology-focused manufacturing company dedicated to broadening access to complex medicines.

  • Roche withdraws Tecentric against a bladder cancer Rajesh Vagh Wed, 11/30/2022 - 15:34

    Roche voluntarily withdraws the U.S. indication of Tecentriq (atezolizumab) for the treatment of adults with locally advanced or metastatic urothelial carcinoma, a bladder cancer.

    An estimated 81,000 cases of bladder cancer will be diagnosed in the United States in 2022. Urothelial carcinoma, which develops in the cells of the bladder lining, is the most common type of bladder cancer, accounting for about 90% of all cases. In total, 30% of cases are considered advanced based on muscle-invasive or metastatic disease.

  • Bharat Biotech Intranasal vaccine receives CDSCO nod for booster Pradip Mahajan Tue, 11/29/2022 - 15:53

    Bharat Biotech International Limited a global leader in vaccine innovation and developer of vaccines for infectious diseases, today announced that iNCOVACC® (BBV154), has received approval from the Central Drugs Standard Control Organisation (CDSCO) under Rcstrictcd Use in Emcrgcncy Situation for ages 18 and above, in India, for heterologous booster doses.

  • AstraZeneca Pharma India get CDSCO nod for Dapagliflozin tablets Rajesh Vagh Mon, 11/28/2022 - 15:53

    AstraZeneca Pharma India has received an import and market permission in Form CT-20 (subsequent new drug approval) from the Central Drugs Standard Control Organisation for Dapagliflozin tablets of 10 mg.

    Through this approval, the Company is permitted to deal in Dapagliflozin (Forxiga®) tablets of 10 mg in additional/expanded indication to reduce the risk of sustained eGFR and kidney disease, cardiovascular death and hospitalization for heart failure in adult with chronic kidney disease at risk of progression with condition.

  • Eli Lilly launches Ramiven in India Rajesh Vagh Fri, 11/25/2022 - 17:06

    Eli Lilly India has announced the launch of the additional indication for Ramiven (abemaciclib), following approval from The Drug Controller General of India (DCGI) in combination with endocrine therapy for adjuvant treatment in adult patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative, node-positive early breast cancer (EBC) at high risk of recurrence.

  • Antitrust case filed against Dr Reddys Labs in US Rajesh Vagh Wed, 11/23/2022 - 17:05

    Antitrust case filed against Dr Reddys Labs in the US over maintaining a shared monopoly in the sale of brand and generic Revlimid through their respective settlements of patent litigation with other pharmaceutical companies.

    Dr Reddys Lab along with Celgene, Bristol Myers Squibb and several generic pharmaceutical companies, were named as defendants in a complaint filed on November 18, 2022, in the District of New Jersey, USA.

  • Amneal Launches Second Biosimilar of filgrastim-ayow in the US Pradip Mahajan Wed, 11/23/2022 - 16:00

    Amneal Pharmaceuticals, Inc announced the commercial launch of RELEUKO® (filgrastim-ayow), a biosimilar referencing Neupogen®. RELEUKO® is used to treat neutropenia which is commonly experienced by patients undergoing chemotherapy. This product was developed in collaboration with Kashiv Biosciences, LLC located in Chicago, Illinois.

Subscribe to Industry News

Search this website